24322 Federal Register / Vol. 87, No. 79 / Monday, April 25, 2022 / Notices 

identifies the product being exported 

(e.g., name, description, and in some 

cases, country of destination) and 

specifies where the notifications were 

sent. These notifications are sent only 

for an initial export. Subsequent exports 

of the same product to the same 

destination or to certain countries 

identified in section 802(b) of the FD&C 

Act would not result in a notification to 

FDA. 

Respondents to the information 

collection are exporters of products that 

may not be sold in the United States and 

are regulated by FDA’s Center for Drug 

Evaluation and Research (CDER); Center 

for Biologics Evaluation and Research 

(CBER); Center for Devices and 

Radiological Health (CDRH); Center for 

Veterinary Medicine (CVM); Center for 

Food Safety and Applied Nutrition 

(CFSAN); and Center for Tobacco 

Products. Respondents to this collection 

of information maintain records 

demonstrating their compliance with 

the requirements in 21 CFR 1.101. 

In the Federal Register of January 25, 

2022 (87 FR 3811), FDA published a 60- 

day notice requesting public comment 

on the proposed collection of 

information. No comments were 

received. 

We estimate the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

21 CFR section Number of 

respondents 

Number of 

responses per 

respondent 

Total annual 

responses 

Average 

burden per 

response 

Total hours 

1.101(d) (CBER) .................................................................. 4 35 140 15 2,100 

1.101(d) (CDER) .................................................................. 3 57 171 15 2,565 

1.101(d) (CDRH) .................................................................. 22 4 88 15 1,320 

Total .............................................................................. ........................ ........................ ........................ ........................ 5,985 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1

21 CFR section Number of 

recordkeepers 

Number of 

records per 

recordkeeper 

Total annual 

records 

Average 

burden per 

recordkeeping 

Total hours 

1.101(b), (c), and (e) (CBER, CDER, CDRH, CFSAN, and 

CVM) ................................................................................ 181 4.12 746 22 16,412 

1.101(b) Office of International Programs only ................... 1 65 65 22 1,430 

1.101(b) (currently regulated Tobacco Products) ................ 322 3 966 22 21,252 

Total .............................................................................. ........................ ........................ ........................ ........................ 39,094 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

Based on a review of Agency data, we 

decreased our estimate by 24,251 

burden hours. This decrease reflects an 

overall downward trend in the number 

of export certification requests across 

programs and commodities. The 

estimate for tobacco products remains 

steady. 

Dated: April 19, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–08739 Filed 4–22–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Special 

Topics: Vision Imaging, Bioengineering and 

Low Vision Technology Development. 

Date: May 25–26, 2022. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Susan Gillmor, Ph.D., 

Scientific Review Officer, National Institutes 

of Health, Center for Scientific Review, 6701 

Rockledge Drive, Bethesda, MD 20892, 240– 

762–3076, susan.gillmor@nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group; Gene and Drug Delivery Systems 

Study Section. 

Date: June 13–14, 2022. 

Time: 9:00 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jain Krotz, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (240) 672–8670 jain.krotz@nih.gov. 

Name of Committee: Vascular and 

Hematology Integrated Review Group; 

Hemostasis, Thrombosis, Blood Cells and 

Transfusion Study Section. 

Date: June 14–15, 2022. 

Time: 10:00 a.m. to 9:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Katherine M Malinda, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4140, 

MSC 7814, Bethesda, MD 20892, (301) 435– 

0912, malindakm@csr.nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group; Instrumentation and Systems 

Development Study Section. 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 79 / Monday, April 25, 2022 / Notices 24323 

Date: June 16–17, 2022. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Kee Forbes, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5148, 

MSC 7806, Bethesda, MD 20892, 301–272– 

4865, pyonkh2@csr.nih.gov. 

Name of Committee: Oncology 2— 

Translational Clinical Integrated Review 

Group; Cancer Biomarkers Study Section. 

Date: June 16–17, 2022. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Lawrence Ka-Yun Ng, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6152, 

MSC 7804, Bethesda, MD 20892, 301–357– 

9318 ngkl@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: April 19, 2022. 

David W Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08716 Filed 4–22–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request International 

Research Fellowship Award Program 

of the National Institute on Drug Abuse 

(NIDA) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, the 

National Institute on Drug Abuse 

(NIDA), National Institutes of Health 

(NIH) has submitted to the Office of 

Management and Budget (OMB) a 

request for review and approval of the 

information collection listed below. 

DATES: Comments regarding this 

information collection are best assured 

of having their full effect if received 

within 30-days of the date of this 

publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this information 

collection by selecting ‘‘Currently under 

30-day Review—Open for Public 

Comments’’ or by using the search 

function. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact: Dr. Lindsey 

Friend, Research Training Program 

Officer, NIDA International Program, 

National Institute on Drug Abuse, 

National Institutes of Health, 3WFN 

MSC 6024, 301 North Stonestreet 

Avenue, Bethesda, Maryland 20892, or 

call non-toll-free number (301) 402– 

1428 or email your request, including 

your address to: lindsey.friend@nih.gov. 

SUPPLEMENTARY INFORMATION: This 

proposed information collection was 

previously published in the Federal 

Register on February 14, 2022, page 

8267 (87 FR 8267) and allowed 60 days 

for public comment. No public 

comments were received. The purpose 

of this notice is to allow an additional 

30 days for public comment. 

The National Institute on Drug Abuse 

(NIDA), National Institutes of Health, 

may not conduct or sponsor, and the 

respondent is not required to respond 

to, an information collection that has 

been extended, revised, or implemented 

on or after October 1, 1995, unless it 

displays a currently valid OMB control 

number. 

In compliance with Section 

3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institutes of Health (NIH) has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. 

Proposed Collection: The 

International Research Fellowship 

Award Program of the National Institute 

on Drug Abuse (NIDA), 0925–0733, 

expiration date 07/31/2022, 

EXTENSION, National Institute on Drug 

Abuse (NIDA), National Institutes of 

Health (NIH). 

Need And Use of Information 

Collection: These programs offer grants 

and traineeships necessary for growing 

the biomedical researcher workforce, 

and the diversity in this workforce. The 

application forms collect information of 

applicants for selecting those that would 

benefit most effectively from the 

programs. NIDA is requesting approval 

from OMB for application forms to be 

used by these programs that will recruit 

pre-college through post-doctoral 

underrepresented individuals and 

individuals of special populations into 

the research programs of the Institute for 

research training and research 

development, for forging mentor/mentee 

relationships and networking between 

newly funded underrepresented 

researchers and experienced 

investigators funded by NIDA; and for a 

fellowship program to train new 

researchers, and support experienced 

researchers of other nations, in research 

to advance the biomedical and 

behavioral science of drug abuse and 

addiction while fostering multinational 

research in this disease area. The 

application forms will be web-based. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

annualized burden hours are 33. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average time 

per response 

(in hours) 

Total annual 

burden hour 

Applicant Scientists .......................................................................................... 25 1 1 25 

Scientists .......................................................................................................... 25 1 20/60 8 

Total .......................................................................................................... ........................ 50 ........................ 33 


khammond on DSKJM1Z7X2PROD with NOTICES